Today, Pan Cancer T BV announced a seed extension financing which was led by Thuja Capital. Pan Cancer T is a spin-off company of Erasmus Medical Center Rotterdam, developing novel adoptive T cell therapeutics aimed to treat cancer.

The company aims to contribute significantly to the treatment of solid tumor indications that currently have a poor prognosis. With this investment, Thuja’s third fund has now added a third company to its portfolio.

For more information on the seed extension financing in Pan Cancer T, we refer to the press release.